Synlogic Inc SYBX

NAS: SYBX | ISIN: US87166L1008   30/04/2025
1,140 USD (-0,87%)
(-0,87%)   30/04/2025

11 augustus 2022 · Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks · Persbericht

23 november 2021 · Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients with Phenylketonuria Treated with SYNB1618 · Persbericht

10 november 2021 · Synlogic Reports Third Quarter Financial Results and Provides Business Update · Persbericht

10 november 2021 · Synlogic Announces Presentation of Phenylketonuria Data at 14th International Congress of Inborn Errors of Metabolism Meeting · Persbericht

9 november 2021 · Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria · Persbericht

2 november 2021 · Synlogic Announces Third Quarter 2021 Conference Call & Participation in Upcoming Banking Conference · Persbericht

28 oktober 2021 · Synlogic Announces Nature Communications Publication Highlighting Use of Synthetic Biotic Platform to Optimize Therapies for Phenylketonuria · Persbericht

15 oktober 2021 · Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021 · Persbericht

12 oktober 2021 · Synlogic Announces Nature Publication Demonstrating Novel Application of Synthetic Biotic Platform · Persbericht

27 september 2021 · Synlogic Appoints Molly Harper as Chief Business Officer · Persbericht

23 september 2021 · Synlogic Announces Pricing of Public Offering of Common Stock · Persbericht

22 september 2021 · Synlogic Announces Proposed Public Offering of Common Stock · Persbericht

20 september 2021 · Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria · Persbericht

10 september 2021 · Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting · Persbericht

10 september 2021 · Synlogic Presents at Global PKU Patient Meeting · Persbericht

12 augustus 2021 · Synlogic Reports Second Quarter Financial Results and Provides Business Update · Persbericht

5 augustus 2021 · Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference · Persbericht

22 juli 2021 · Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platform for the Treatment of Phenylketonuria (PKU) · Persbericht

15 juli 2021 · Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU) · Persbericht

17 juni 2021 · Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease · Persbericht

Mijn selecties